Credit: Caitlin Koppenhaver
Florida is signaling an important message in the compounding and weight-loss ecosystem: the Florida Legislature is not waiting for federal enforcement to catch up. Florida Senate Bill 860 (2026), filed on December 10, expressly states that while the FDA sets internationally recognized standards and bears the “responsibility for enforcing federal laws to protect citizens from misbranded and adulterated pharmaceutical ingredients”, FDA enforcement has “proven insufficient” to stop “illicit, substandard, and potentially harmful active pharmaceutical ingredients that jeopardize patient health and safety”.
The Florida Legislature “therefore finds it necessary for the state to take action to protect its residents by ensuring that all active pharmaceutical ingredients used in compounding are sourced from reputable, registered, and inspected establishments, and that only pharmaceutical-grade, safe, and unadulterated ingredients are used in medications for weight loss”. This proposed section will not be in the Florida Pharmacy Practice Act (Chapter 465), but instead is introduced as a new section proposed in the Florida Drug and Cosmetic Act (Chapter 499), the part of Florida law that focuses on drug distribution, adulteration/misbranding concepts, and supply chain controls.
What would this mean if enacted?
Under this proposed section titled “Regulation of medications containing certain active pharmaceutical ingredients”, the term “compounded medication” would be defined as “a customized drug prepared by a licensed pharmacist or licensed physician by combining, mixing, or altering the ingredients of one or more drugs or products, which drug is commonly prescribed if a commercially available medication does not meet a patient’s specific health need.”
If this bill becomes law, it would prohibit a person or entity from engaging in the sale, transfer, or distribution of a compounded medication for weight loss unless the person or entity provides documentation to the Department of Business and Professional Regulation certifying all of the following:
1. FDA-approved drug “match” requirement: If the weight-loss compound is being compounded by a licensed pharmacist or licensed physician pursuant to the federal provision that allows compounding from bulk drug substances (Section 503A of the FD&C Act), the active pharmaceutical ingredient must be (i) identical to that used in the manufacture of an FDA-approved drug and (ii) manufactured according to the manufacturing process for that ingredient as specified on the label of an FDA-approved drug.
2. Pharmaceutical-grade requirement: The active pharmaceutical ingredient (API) must be a pharmaceutical-grade product.
3. Certificate of Analysis (COA) plus underlying data: The API must be accompanied by a valid COA that includes informational material as to the safety and effectiveness of the drugs compounded using the active pharmaceutical ingredient, including the identity and content of the active pharmaceutical ingredient and the identity of each impurity by chemical name and amount present. A certificate of analysis is not valid unless it is accompanied by testing data from the original manufacturing establishment demonstrating that the information on the certificate of analysis is accurate.
4. FDA registration and recent inspection requirement: The API must be manufactured in a facility that is FDA-registered pursuant to 21 U.S.C. s. 360 and has been inspected by FDA as a human drug establishment within the past two years. The inspection must have included monitoring for cGMP compliance for the relevant API and must have resulted in an FDA classification of either NAI (No Action Indicated) or VAI (Voluntary Action Indicated).
5. Incoming quality control testing requirement: Quality control testing of the API must be conducted before use in a compounded drug to confirm the API’s identity and content and to confirm (i) the identity and content of the active pharmaceutical ingredient and (ii) that any impurity present has been identified, characterized, quantified, and justified given the product or the product’s intended use.
Violations of this section would trigger a fine of $1,000 per dose of the “illegally compounded” drug sold, dispensed, transferred, or distributed and subject the person or entity to license or permit revocation by the Board of Pharmacy or the Department of Business and Professional Regulation, as applicable. DBPR may adopt implementing rules and conduct inspections as necessary, and the section would take effect upon becoming law.
Who would this apply to?
SB 860 would apply to any person or entity that sells, transfers, or distributes compounded weight-loss medications in Florida, which functionally includes compounding pharmacies and dispensing providers, as well as any distributor or permitted entity involved in delivering the product or its APIs through the supply chain.
Will this pass?
As of the last posted action, SB 860 has been filed and then referred to three Senate committees: Regulated Industries (RI), Appropriations Committee on Agriculture, Environment, and General Government (AEG), and Fiscal Policy (FP). The bill would then need to pass the full Senate and the House (with any differences reconciled into identical final text), and then be signed by the Governor (or enacted over a veto).
Practical Takeaways
In the meantime, this proposal is a useful compliance “direction-of-travel” signal even if it does not ultimately pass. Industry stakeholders can use it as a practical checklist now by identifying every compounded weight-loss product in scope, confirming the API’s source and inspection status, organizing COAs and underlying manufacturer test data, documenting incoming API testing before use, and tightening vendor qualification files and contracts so suppliers must provide these materials on demand. Even if SB 860 stalls, these steps reflect where Florida legislators appear to be headed on weight-loss compounding and supply-chain expectations.
Source: flsenate.gov/Session/Bill/2026/860/BillText/Filed/HTML
